Trial Profile
A Randomized, Double-blind, Placebo-controlled Single Multiple Dosing, Dose Escalation Phase I Clinical Trial to Investigate HY209 Gel in Healthy Male Volunteers as a Possible Treatment Option for Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2021
Price :
$35
*
At a glance
- Drugs Taurodeoxycholic-acid (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Shaperon
- 17 Mar 2021 Results presented at the 122nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 24 Feb 2020 Status changed from recruiting to completed.
- 08 Apr 2019 Planned End Date changed from 1 Dec 2018 to 30 Aug 2019.